- Home
- USIO vs BCAB Comparison
USIO vs BCAB Comparison
Compare USIO & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- BCAB
- Stock Information
- Founded
- USIO 1998
- BCAB 2007
- Country
- USIO United States
- BCAB United States
- Employees
- USIO N/A
- BCAB N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- USIO Finance
- BCAB Health Care
- Exchange
- USIO Nasdaq
- BCAB Nasdaq
- Market Cap
- USIO 37.6M
- BCAB 40.5M
- IPO Year
- USIO N/A
- BCAB 2020
- Fundamental
- Price
- USIO $1.44
- BCAB $0.70
- Analyst Decision
- USIO Strong Buy
- BCAB Hold
- Analyst Count
- USIO 1
- BCAB 3
- Target Price
- USIO $4.00
- BCAB $1.00
- AVG Volume (30 Days)
- USIO 72.5K
- BCAB 1.5M
- Earning Date
- USIO 11-05-2025
- BCAB 11-05-2025
- Dividend Yield
- USIO N/A
- BCAB N/A
- EPS Growth
- USIO N/A
- BCAB N/A
- EPS
- USIO 0.11
- BCAB N/A
- Revenue
- USIO $83,851,606.00
- BCAB $11,000,000.00
- Revenue This Year
- USIO $8.71
- BCAB N/A
- Revenue Next Year
- USIO $12.48
- BCAB N/A
- P/E Ratio
- USIO $13.28
- BCAB N/A
- Revenue Growth
- USIO 2.05
- BCAB N/A
- 52 Week Low
- USIO $1.24
- BCAB $0.24
- 52 Week High
- USIO $2.92
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- USIO 49.86
- BCAB 48.71
- Support Level
- USIO $1.43
- BCAB $0.66
- Resistance Level
- USIO $1.47
- BCAB $1.06
- Average True Range (ATR)
- USIO 0.05
- BCAB 0.12
- MACD
- USIO 0.01
- BCAB -0.02
- Stochastic Oscillator
- USIO 63.81
- BCAB 19.11
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.